Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Kansas Business Today.
Press releases published on May 14, 2025

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Corporate R…

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 SAN …

USA Rare Earth Reports its First Quarter 2025 Financial Results
STILLWATER, Okla., May 14, 2025 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (“USAR” or the “Company”) today announced its financial results for the first quarter ended March 31, 2025. First Quarter Highlights Merged with Inflection Point and …

IREN Reports Q3 FY25 Results
28% Growth in Profit After Tax Horizon 1 AI Data Center on Track for H2 2025 Pausing Mining Expansion at 50 EH/s to Focus on AI Opportunities SYDNEY, May 14, 2025 (GLOBE NEWSWIRE) -- IREN Limited (NASDAQ: IREN) (together with its subsidiaries, “IREN” or “ …

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity …

The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance
CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months …

Fossil Group, Inc. Reports First Quarter 2025 Financial Results
RICHARDSON, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- First quarter worldwide net sales totaled $233 million Gross margin expanded 890 basis points to 61.3% First quarter operating loss of $7 million; constant currency adjusted operating income of $10 …

Lulus Reports First Quarter 2025 Results
Significant Improvement in Liquidity with $1.4M Increase in Cash Provided by Operating Activities and $1.8M Increase in Free Cash Flow, Both Compared to Q1’24 Reduced Total Debt by $3.0M and Net Debt by $7.2M During Q1’25 CHICO, Calif., May 14, 2025 (GLOBE …

Hawkins, Inc. Reports Fourth Quarter and Fiscal Year 2025 Results
ROSEVILLE, Minn., May 14, 2025 (GLOBE NEWSWIRE) -- Hawkins, Inc. (Nasdaq: HWKN) today announced fourth quarter and full-year results for its fiscal year ended March 30, 2025. Fourth Quarter Fiscal Year 2025 Highlights: Record fourth quarter sales of $245.3 …

Castor Maritime Inc. Reports Fourth Quarter and Full Year Results for 2024
LIMASSOL, Cyprus, May 14, 2025 (GLOBE NEWSWIRE) -- Castor Maritime Inc. (NASDAQ: CTRM) (“Castor” or the “Company”), a diversified global shipping and energy company, today announced its results for the three months and year ended December 31, 2024. …

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination
WILMINGTON, Del., May 14, 2025 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline …

Castor Maritime Inc. Announces Availability of its 2024 Annual Report on Form 20-F
LIMASSOL, Cyprus, May 14, 2025 (GLOBE NEWSWIRE) -- Castor Maritime Inc. (NASDAQ: CTRM), (“Castor”, or the “Company”), a diversified global shipping and energy company, announces that the Company’s annual report on Form 20‐F (the “Annual Report”), which …

Aterian Reports 2025 First Quarter Financial Results
SUMMIT, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”), a consumer products company, today announced financial results for the first quarter ended March 31, 2025 (“Q1 2025”). The Company also provided an …

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer
CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief …

Shimmick Corporation Announces First Quarter 2025 Results
IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Shimmick Corp. (NASDAQ: SHIM), a leading infrastructure solutions provider in water, climate resilience, energy transition and sustainable transportation, today announced financial results for the first …

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025
PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential …

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million …

STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic …

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim …